{
  "_id": "350fa279d071fdff8f1170160227bbf47ad2579c2c535f281f3722e0cef9c99c",
  "feed": "ftcomall",
  "title": "Clarification: Efficacy rates",
  "text": "<p>The Sputnik V Covid-19 vaccine's general efficacy of 92 per cent compares with 66.9 per cent overall efficacy of the Johnson &amp; Johnson vaccine. An <a href=\"https://www.ft.com/content/ffe40c7d-c418-4a93-a202-5ee996434de7\">article</a> on February 26 compared the Sputnik V general efficacy level with J&amp;J rates of efficacy in preventing severe or critical disease of more than 80 per cent.</p><p>Source:  2021 'Clarification: Efficacy rates' FT.com 3 March. Used under licence from the Financial Times. Â© The Financial Times Limited 2021. All Rights Reserved. </p><p>Please do not cut and paste FT articles and redistribute by email or post to the web.</p>",
  "published": "2021-03-03T23:28:26.542Z",
  "tags": [
    {
      "id": "US4781601046",
      "name": "Johnson & Johnson",
      "offsets": [
        {
          "start": 117,
          "end": 134
        },
        {
          "start": 221,
          "end": 224
        }
      ],
      "nexusId": "10010560"
    }
  ]
}